CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Quinacrinedrug
Likely dose
Quinacrine 100 mg dailyAI-extracted
Key inclusion· 6
  • ✓Male patients ≥18 years with pathologically confirmed prostate adenocarcinoma
  • ✓Androgen-independent metastatic prostate cancer with radiologic metastases and castrate testosterone levels (~50 ng/dL)
  • ✓Must be receiving ongoing androgen suppression via LHRH agonists or bilateral orchiectomy
  • ✓Prior chemotherapy with docetaxel or mitoxantrone, or refused/ineligible for chemotherapy
Key exclusion· 14
  • ✕Prior allergic reactions or intolerance to quinacrine or other acridine derivatives
  • ✕Lifetime history of porphyria or psoriasis
  • ✕Documented glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • ✕Lifetime history of seizure disorder (except infant febrile seizures)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00417274
NCT00417274Phase 2Completed
CompareCT.gov

An Open-Label, Phase II Safety, Tolerability, Drug Level and Efficacy Trial of Quinacrine in Patients With Androgen-Independent Metastatic Prostate Cancer

Cleveland BioLabs·interventional·Posted Dec 29, 2006·Updated Apr 11, 2013

In Brief

A Phase 2 clinical trial evaluating Quinacrine for Prostatic Cancer. Completed, enrolled 31 participants.

Detailed Summary

The purpose of this study is to determine whether quinacrine is effective in the treatment of Androgen-Independent Prostate Cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Cancer
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 29, 2006
Enrollment StartDec 1, 2006
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.5 years ago

Interventions

Quinacrinedrug

100 mg daily